KIT oncoprotein interactions in gastrointestinal stromal tumors: Therapeutic relevance

Oncogene

Volumn 26, Issue 44, 2007, Pages 6386-6395

  Zhu, M J ^a,b   Ou, W B ^a,b   Fletcher, C D M ^a,b   Cohen, P S ^c   Demetri, G D ^b,d   Fletcher, J A ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Interaction; Kinase; KIT; PDGFRA; Signal transduction

Indexed keywords

EPHRIN RECEPTOR A4; IMATINIB; JANUS KINASE 1; KIT ONCOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE C THETA; STAT1 PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY AFFINITY; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; DRUG RESISTANCE, NEOPLASM; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOPRECIPITATION; MUTATION; PHOSPHORYLATION; PROTEIN KINASE C-DELTA; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RNA, SMALL INTERFERING; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED; TYROSINE;

EID: 34848883114     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210464     Document Type: Article

References (22)

1. Blume-Jensen P, Janknecht R, Hunter T. (1998). The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136. Curr Biol 8: 779-782.
2. Debiec-Rychter M, Cools J, Dumez H, Sciot R, Stul M, Mentens N et al. (2005). Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 128: 270-279.
3. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ et al. (2002). Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480.
4. Duensing A, Joseph NE, Medeiros F, Smith F, Hornick JL, Heinrich MC et al. (2004a). Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). Cancer Res 64: 5127-5131.
5. Duensing A, Medeiros F, McConarty B, Joseph NE, Panigrahy D, Singer S et al. (2004b). Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene 23: 3999-4006.
6. Fabbro D, Ruetz S, Bodis S, Pruschy M, Csermak K, Man A et al. (2000). PKC412 - a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 15: 17-28.
7. Hallek M, nhauser-Riedl S, Herbst R, Warmuth M, Winkler A, Kolb HJ et al. (1996). Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells. Br J Haematol 94: 5-16.
8. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N et al. (2003). PDGFRAactivating mutations in gastrointestinal stromal tumors. Science 299: 708-710.
9. Heinrich MC, Rubin BP, Longley BJ, Fletcher JA. (2002). Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 33: 484-495.
10. Herbst R, Shearman MS, Jallal B, Schlessinger J, Ullrich A. (1995). Formation of signal transfer complexes between stem cell and platelet-derived growth factor receptors and SH2 domain proteins in vitro. Biochemistry 34: 5971-5979.
11. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S et al. (1998). Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577-580.
12. Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y et al. (2003). Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 125: 660-667.
13. Medeiros F, Corless CL, Duensing A, Hornick JL, Oliveira AM, Heinrich MC et al. (2004). KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 28: 889-894.
14. Ning ZQ, Li J, Arceci RJ. (2001). Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells. Blood 97: 3559-3567.
15. Otto KG, Jin L, Spencer DM, Blau CA. (2001). Cell proliferation through forced engagement of c-Kit and Flt-3. Blood 97: 3662-3664.
16. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R et al. (2001). KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61: 8118-8121.
17. Saucier C, Papavasiliou V, Palazzo A, Naujokas MA, Kremer R, Park M. (2002). Use of signal specific receptor tyrosine kinase oncoproteins reveals that pathways downstream from Grb2 or Shc are sufficient for cell transformation and metastasis. Oncogene 21: 1800-1811.
18. Sordella R, Bell DW, Haber DA, Settleman J. (2004). Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163-1167.
19. Tauchi T, Feng GS, Marshall MS, Shen R, Mantel C, Pawson T et al. (1994). The ubiquitously expressed Syp phosphatase interacts with c-kit and Grb2 in hematopoietic cells. J Biol Chem 269: 25206-25211.
20. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD et al. (2001). STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20: 5054-5058.
21. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY et al. (2004). Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364: 1127-1134.
22. Vultur A, Cao J, Arulanandam R, Turkson J, Jove R, Greer P et al. (2004). Cell-to-cell adhesion modulates Stat3 activity in normal and breast carcinoma cells. Oncogene 23: 2600-2616.